Company Overview and News
Welcome to the Atos First Half 2017 Results Conference Call. Today's conference is being recorded. At this time, I would like to turn the conference over to Thierry Breton, Chairman and CEO. Please go ahead.
This report analyzes the worldwide markets for Hydraulic Components in US$ Million by the following Product Segments: Accumulators and Filters, Cylinders, Power Packs, Pumps and Motors, Valves, and Other Hydraulic Components.
LONDON, March 8, 2017 /PRNewswire/ -- "Variable displacement pumps market projected to register a CAGR of 4.1%"
Good morning ladies and gentlemen. Thierry Breton speaking. Thank you for attending Atos conference call today for our result of 2016. So, I'm going to share this presentation together with Elie Girard, our Group CFO, Patrick Adiba, in charge of global sales and also here in the room, Charles Dehelly and Michel-Alain Proch, SEVPs. I will start with the key figures of the year. Then I will quickly update you on the Group strategy and present the 2017 guidance.
Two private firms have earned more than £500m in taxpayers’ money for carrying out controversial work capability assessments.
Fit-to-work firms Atos and Capita have earned more than £500m of taxpayer cash running a hated Tory scheme to assess people for disability benefits.
The Q3 earnings season is drawing to a close, with 423 of the S&P 500 Index members having released results so far. Reported earnings were up 3.6% year over year on 2.4% higher revenues. This week too will see a string of earnings releases from more than 650 companies (including 31 S&P members). Overall, for the S&P 500 members, projections are of a 3% improvement in earnings on 1.5% higher revenues despite an expected 63.
NEW YORK, Aug. 8, 2016 /PRNewswire/ -- "Variable displacement pumps market projected to register a CAGR of 4.1%" The market size of variable displacement pumps is projected to reach USD 4.03 billion by 2021, registering a CAGR of 4.1% between 2016 and 2021. The growth is primarily triggered by its huge demand from the Asia-Pacific region and the growing end-use industries such as construction, mining, automotive, agriculture, and others.
The report "Variable Displacement Pumps Market by Type (Piston and Vane), Application (Hydraulic and IC Engine), End-use Industry (Construction, Mining, Automotive, Agriculture, Plastic, and Material Handling) - Global Trends & Forecasts to 2021", published by MarketsandMarkets, The global market is projected to reach USD 4.03 Billion by 2021, registering a CAGR of 4.1% between 2016 and 2021.
Atos Origin SA (OTCPK:AEXAF) First Half 2016 Results Earnings Conference Call July 26, 2016 12:00 PM ET
NEW YORK, NY--(Marketwired - Mar 16, 2016) - EMC Corporation (NYSE: EMC), ImageWare Systems (OTCQB: IWSY); Route1 (TSX VENTURE: ROI).
Atos Origin SA ADR (OTCPK:AEXAY) Q4 2015 Earnings Conference Call February 25, 2016 2:00 AM ET Executives Thierry Breton - Chairman and Chief Executive Officer
2018-05-21 - Asif
Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...
2018-05-21 - Asif
Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...
2018-05-21 - Asif
Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...